Jason Lewis Radiochem MSK

Final places are still available to attend the Cancer Grand Challenges Conference: Cancer and the host If you’re interested in exploring cancer as a systemic disease and joining thought leaders from across the cancer research spectrum to discuss and debate how the unique biology of each individual shapes cancer development and treatment response, this is a meeting you won’t want to miss. Register now to secure your place: eventbrite.co.uk/e/grand-challe… 🗓️ Wednesday 17 – Friday 19 June 2026 🚨 Registration closes Friday 1 May 2026 📍 The Royal Society, London @MarcusDGon, Professor Caroline Dive. CBE, @diggy5353 , @giampazolias, Mariam Jamal-Hanjani, @Joycelab, @LewisLabMSKCC, @lynchielydia , Stephen o'rahilly, Marco Sandri, Erica Sloan, Claudio Vernieri, Ashani Weeraratna, @EileenWhitePhD and Frank Winkler @CR_UK @NCICancerTrials

It’s out “Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model”led by @ECharlesPratt et al aacrjournals.org/clincancerres/…

MSK radiochemist @LewisLabMSKCC shared an insightful presentation about questions and new opportunities in #theranostics at #AACR26. @AACR

Our paper "Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix–Targeted Radiopharmaceutical against Triple-Negative Breast Cancer" is out. …journals-org.eu1.proxy.openathens.net/clincancerres/… The thesis work of @Just_Hachey. Added bonus - we got the cover of CCR!

Find out more at saulhertzmd.com

Wonderful to see Barbara Hertz today on the 85th anniversary of Dr Saul Hertz’s first-in-human radioiodine therapy. A landmark that helped launch theranostics, and targeted precision oncology. Still, we are just at the beginning of the theranostic revolution.

Final call for abstracts! This week is the last chance to submit your abstract for the Cancer Grand Challenges Conference: Cancer and the host cancergrandchallenges.org/conferences/ca… 🚨 Submit by Friday 20 March for the opportunity to join an outstanding line-up of speakers #CancerGrandChallenges #CancerResearch

Dear SNMMI Colleagues: My name will be on the SNNMI ballot for Vice-President Elect (SNNMI President 2028-2029). Voting starts March 30th. If you are a member of the SNMMI, I am hoping you will consider voting for me. My platform statement will be on the ballot. Thank you!

A clinically relevant roadmap for translating CLDN18.2-targeted immuno-PET and radiotherapy for patients with HER2-negative gastric cancer: ow.ly/UgsG50YpNL8. #NuclearMedicine #RPTherapy #GastricCancer @TheZeglisLab @YJanjigianMD @LewisLabMSKCC

Fabulous visit to Riken in Tokyo today - and the most impressive cyclotron I have ever seen….

The “Cycletrons” (the best name ever!) raising money for an amazing cause - curing rare cancer!! @MSKCancerCenter @Equinox @Cycle4Survival

Read our latest - out now at EJNMMI “Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer”. rdcu.be/e6awn

Our latest “Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer” jnm.snmjournals.org/content/early/…

The “Cycletrons” are participating in @Cycle4Survival to raise money for rare cancer research at @MSKCancerCenter, and your support would mean so much to us. Make a 100% tax-deductible donation using the link. Thank you! secure2.convio.net/mskcc/site/TR?…

What's next in DLL3-targeted therapy for NECs...? Maybe this... pnas.org/doi/10.1073/pn…

Proud to see our work featured: a DLL3-targeted theranostic approach from @MSKCancerCenter combining PET imaging and targeted therapy for aggressive small cell lung and neuroendocrine prostate cancers.⁦@MSKCancerCenter⁩ ⁦@LewisLabMSKCC⁩ mskcc.org/news/new-imagi…

Very proud to share our full discovery campaign identified a next-generation DLL3 antibody that outperformed first-gen antibodies in imaging and therapy with minimal toxicity. Huge thanks to our incredible co-authors and @PCFnews for making this possible! pnas.org/doi/10.1073/pn…

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers | PNAS pnas.org/doi/10.1073/pn…

This was actually really interesting to do and to look back and reflect “Leading Through Change: Reflections from Jason Lewis” jnm.snmjournals.org/content/early/…